COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

被引：216

作者：

Mitchell, JA

Warner, TD

机构：

[1] Royal Brompton Hosp, Imperial Coll Sch Med, Natl Heart & Lung Inst, Unit Crit Care Med, London SW3 6LY, England

[2] Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 01期

关键词：

D O I：

10.1038/nrd1929

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the formation of prostanoids by the enzyme cyclooxygenase ( COX). Work in the past 15 years has shown that COX exists in two forms: COX1, which is largely associated with physiological functions, and COX2, which is largely associated with pathological functions. Heated debate followed the introduction of selective COX2 inhibitors around 5 years ago: do these drugs offer any advantages over the traditional NSAIDs they were meant to replace, particularly in regard to gastrointestinal and cardiovascular side effects? Here we discuss the evidence and the latest recommendations for the use of selective inhibitors of COX2 as well as the traditional NSAIDs.

引用

页码：75 / 85

页数：11

共 102 条

[1] The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor [J].

Alsalameh, S ;

Burian, M ;

Mahr, G ;

Woodcock, BG ;

Geisslinger, G .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (04) :489-501

[2] Cyclooxygenase inhibition and cardiovascular risk [J].

Antman, EM ;

DeMets, D ;

Loscalzo, J .

CIRCULATION, 2005, 112 (05) :759-770

[3] Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes [J].

Aronoff, DM ;

Boutaud, O ;

Marnett, LJ ;

Oates, JA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :589-595

[4] Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition [J].

Athirakul, K ;

Kim, HS ;

Audoly, LP ;

Smithies, O ;

Coffman, TM .

KIDNEY INTERNATIONAL, 2001, 60 (06) :2324-2329

[5] Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages [J].

Baker, CSR ;

Hall, RJC ;

Evans, TJ ;

Pomerance, A ;

Maclouf, J ;

Creminon, C ;

Yacoub, MH ;

Polak, JM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :646-655

[6]

Belton O, 2000, CIRCULATION, V102, P840

[7] Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle - Role of endogenous prostanoids [J].

Bishop-Bailey, D ;

Pepper, JR ;

Larkin, SW ;

Mitchell, JA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) :1655-1661

[8] Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery [J].

BishopBailey, D ;

Pepper, JR ;

Haddad, EB ;

Newton, R ;

Larkin, SW ;

Mitchell, JA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (09) :1644-1648

[9] Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases [J].

Boutaud, O ;

Aronoff, DM ;

Richardson, JH ;

Marnett, LJ ;

Oates, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :7130-7135

[10] Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow [J].

Brooks, AR ;

Lelkes, PI ;

Rubanyi, GM .

PHYSIOLOGICAL GENOMICS, 2002, 9 (01) :27-41

← 1 2 3 4 5 6 7 8 9 10 →